Pharmaceuticals & Drugs
|Market Cap||1,941 Cr||EPS||64.5||High||1524.85|
|Stock P/E||23.5||Net Profit Margin||13.1||Low||1425|
Neuland Labs Price chart
|Market Cap||1,941 Cr||ROE||7.9%|
|P/B Ratio||2.2||Dividend Yield||0.3%|
|Industry P/E||65.7||Book Value||683.0|
About the Company
Named after Father Nieuwland of Notre dame, Neuland Laboratories was incorporated in 1984 by Dr. D. R. Rao for the manufacture of Salbutamol Sulphate, with mere 40 employees.
It has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.
Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery. Neuland is a quality conscious, research driven, reliable source of active pharmaceutical ingredients.
Operating from India for over two decades, Neuland is the preferred source for the Pharmaceutical Industry across the globe, with strengths in Research based Chemistry and Manufacturing.
The Company has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery.
Neuland has two world-class API manufacturing facilities close to the city of Hyderabad, capable in handling complex and hazardous reactions. Safety aspects have been given utmost significance may it be plant installation, equipment, systems and personnel to ensure smooth productivity. Dedicated team of manufacturing with incorporation of latest production techniques guarantees delivery of latest intermediate and product to our customers across the globe.
Product range of the company includes:
- Anti -Asthmatics
- Received a string of regulatory approvals from USFDA & EDQM for its major products (e.g., Ciprofloxacin HCl, Salbutamol Sulphate) USFDA systems inspection for its pashamylaram Facility (Unit-II) in the year 1999
- USFDA systems inspection for its Bonthapally (Unit-I) bringing both facilities under full cGMP compliance in 2004
- Received cGMP clearance for both facilities from TGA, Australia in 2004.
- Certificate of suitability for product itraconazole in 2006.
|Parent Organisation||Neuland Laboratories Ltd.||Managing Director||Davuluri Saharsh Rao|
All values are in Rs Cr
|Company||52 Week||Market Price||P/E Ratio||Financials||Share Holding|